Cellular Immunity Against Cytomegalovirus and Risk of Infection After Kidney Transplantation

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Jul 15

PMID 39007131

Authors

Kjersti B Blom

Grete B Kro

Karsten Midtvedt

Trond G Jenssen

Anna Varberg Reisaeter

Hallvor Rollag

Anders Hartmann

Solbjorg Sagedal

Ivar Sjaastad

Garth Tylden

Gro Njolstad

Einar Nilsen

Jon A Birkeland

Anders Asberg

Affiliations

Soon will be listed here.

Abstract

Introduction: Cytomegalovirus (CMV) infection remains a challenge following kidney transplantation (KTx). Currently, CMV-IgG serostatus at transplantation is used to individualize CMV preventive strategies. We assessed the clinical utility of CMV-IGRA for predicting CMV infection following KTx.

Methods: We performed a nationwide prospective cohort study from August 2016 until December 2022. Data from all adult KTx recipients in Norway, n=1,546 (R+; n=1,157, D+/R-; n=260, D-/R-; 129), were included with a total of 3,556 CMV-IGRA analyses (1,375 at KTx, 1,188 at eight weeks, 993 one-year after KTx) and 35,782 CMV DNAemia analyses.

Results: In R+ recipients CMV-IGRA status, measured at any of the time-points, could not identify any differential risk of later CMV infection. D+/R- recipients remaining CMV-IGRA negative 1-year after transplantation (regardless of positive CMV DNAemia and/or CMV IgG status at that time) had increased risk of developing later CMV infection compared to D+/R- recipients who had become CMV-IGRA positive (14% vs. 2%, p=0.01).

Conclusion: Knowledge of pre-transplant CMV-IGRA status did not provide additional information to CMV-IgG serostatus that could improve current post-transplant CMV treatment algorithms. However, D+/R- recipients with a persisting negative CMV-IGRA one-year after transplantation remained at increased risk of experiencing later CMV infection. Therefore we advocate post-transplant CMV-IGRA monitoring in these patients.

References

Kumar D, Mian M, Singer L, Humar A . An Interventional Study Using Cell-Mediated Immunity to Personalize Therapy for Cytomegalovirus Infection After Transplantation. Am J Transplant. 2017; 17(9):2468-2473. DOI: 10.1111/ajt.14347. View

Andreani M, Albano L, Benzaken S, Cassuto E, Jeribi A, Caramella A . Monitoring of CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients With a High Risk of CMV Disease (D+/R-): A Case Series. Transplant Proc. 2020; 52(1):204-211. DOI: 10.1016/j.transproceed.2019.11.002. View

Crough T, Khanna R . Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev. 2009; 22(1):76-98, Table of Contents. PMC: 2620639. DOI: 10.1128/CMR.00034-08. View

Schachtner T, Stein M, Reinke P . CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor. Transplantation. 2017; 101(10):e315-e325. DOI: 10.1097/TP.0000000000001825. View

Reusing Jr J, Agena F, Kotton C, Campana G, Pierrotti L, David-Neto E . QuantiFERON-CMV as a Predictor of CMV Events During Preemptive Therapy in CMV-seropositive Kidney Transplant Recipients. Transplantation. 2023; 108(4):985-995. DOI: 10.1097/TP.0000000000004870. View

Blom K, Birkeland G, Midtvedt K, Jenssen T, Reisaeter A, Rollag H . Cytomegalovirus High-risk Kidney Transplant Recipients Show No Difference in Long-term Outcomes Following Preemptive Versus Prophylactic Management. Transplantation. 2023; 107(8):1846-1853. PMC: 10358437. DOI: 10.1097/TP.0000000000004615. View

Kumar D, Chernenko S, Moussa G, Cobos I, Manuel O, Preiksaitis J . Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant. 2009; 9(5):1214-22. DOI: 10.1111/j.1600-6143.2009.02618.x. View

Pongsakornkullachart K, Chayakulkeeree M, Vongwiwatana A, Kantakamalakul W, Skulratanasak P, Phoompoung P . QuantiFERON-Cytomegalovirus Assay for Prediction of Cytomegalovirus Viremia in Kidney Transplant Recipients: Study From High Cytomegalovirus Seroprevalence Country. Front Cell Infect Microbiol. 2022; 12:893232. PMC: 9135039. DOI: 10.3389/fcimb.2022.893232. View

Smedbraten Y, Sagedal S, Leivestad T, Mjoen G, Osnes K, Rollag H . The impact of early cytomegalovirus infection after kidney transplantation on long-term graft and patient survival. Clin Transplant. 2013; 28(1):120-6. DOI: 10.1111/ctr.12288. View

10.

Cantisan S, Lara R, Montejo M, Redel J, Rodriguez-Benot A, Gutierrez-Aroca J . Pretransplant interferon-γ secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation. Am J Transplant. 2013; 13(3):738-45. DOI: 10.1111/ajt.12049. View

11.

Deborska-Materkowska D, Perkowska-Ptasinska A, Sadowska A, Gozdowska J, Ciszek M, Serwanska-Swietek M . Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients. BMC Infect Dis. 2018; 18(1):179. PMC: 5902940. DOI: 10.1186/s12879-018-3075-z. View

12.

Fowler K, Mucha J, Neumann M, Lewandowski W, Kaczanowska M, Grys M . A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development. BMC Public Health. 2022; 22(1):1659. PMC: 9435408. DOI: 10.1186/s12889-022-13971-7. View

13.

Cantisan S, Rodelo-Haad C, Paez-Vega A, Nieto A, Vaquero J, Poyato A . Factors related to the development of CMV-specific CD8+ T cell response in CMV-seropositive solid organ transplant candidates. Am J Transplant. 2015; 15(3):715-22. DOI: 10.1111/ajt.13012. View

14.

Razonable R . Cytomegalovirus in Solid Organ Transplant Recipients: Clinical Updates, Challenges and Future Directions. Curr Pharm Des. 2020; 26(28):3497-3506. DOI: 10.2174/1381612826666200531152901. View

15.

Valle-Arroyo J, Aguado R, Paez-Vega A, Perez A, Gonzalez R, Fornes G . Lack of cytomegalovirus (CMV)-specific cell-mediated immune response using QuantiFERON-CMV assay in CMV-seropositive healthy volunteers: fact not artifact. Sci Rep. 2020; 10(1):7194. PMC: 7188901. DOI: 10.1038/s41598-020-64133-x. View

16.

Jarque M, Crespo E, Melilli E, Gutierrez A, Moreso F, Guirado L . Cellular Immunity to Predict the Risk of Cytomegalovirus Infection in Kidney Transplantation: A Prospective, Interventional, Multicenter Clinical Trial. Clin Infect Dis. 2020; 71(9):2375-2385. DOI: 10.1093/cid/ciz1209. View

17.

Kotton C, Kumar D, Caliendo A, Huprikar S, Chou S, Danziger-Isakov L . The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018; 102(6):900-931. DOI: 10.1097/TP.0000000000002191. View

18.

Sagedal S, Nordal K, Hartmann A, DeGre M, Holter E, Foss A . A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation. 2000; 70(8):1166-74. DOI: 10.1097/00007890-200010270-00007. View

19.

Storset E, Asberg A, Hartmann A, Reisaeter A, Holdaas H, Skauby M . Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience. Nephrology (Carlton). 2016; 21(10):821-7. DOI: 10.1111/nep.12738. View

20.

Sagedal S, Hartmann A, Nordal K, Osnes K, Leivestad T, Foss A . Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int. 2004; 66(1):329-37. DOI: 10.1111/j.1523-1755.2004.00735.x. View